NCT03680677 Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
| NCT ID | NCT03680677 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Leukemia, Acute |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2018-09-21 |
| Primary Completion | 2026-06-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2018-09-21 with a primary completion date of 2026-06-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
Eligibility Criteria
Eligibility Criteria Arm A: * Age 60 years or older. * New diagnosis of Acute Leukemia or MDS, or suspected diagnosis. * Able to consent to the study. Eligibility Criteria Arm B: * Age 60 years or older with a hematologic malignancy. * Plan to undergo an allogeneic blood or marrow transplantation or CAR T-cell therapy. * Able to consent to the study.
Contact & Investigator
Shannon McCurdy, MD
PRINCIPAL INVESTIGATOR
Abramson Cancer Center
Frequently Asked Questions
Who can join the NCT03680677 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Leukemia, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03680677 currently recruiting?
Yes, NCT03680677 is actively recruiting participants. Contact the research team at penncancertrials@emergingmed.com for enrollment information.
Where is the NCT03680677 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT03680677 clinical trial?
NCT03680677 is sponsored by Abramson Cancer Center at Penn Medicine. The principal investigator is Shannon McCurdy, MD at Abramson Cancer Center. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.